The world’s population is aging at an unprecedented pace. According to WHO’s October 2024 report, the number of people aged 60 and older surpassed children under five for the first time in 2020. By ...

Johnson & Johnson may outshine AbbVie as a top defensive stock pick. Read how Ben Graham's framework evaluates each ...

AbbVie's growth thrives on strong earnings, a robust immunology portfolio, and diversification. See why ABBV stock is a ...

Large American pharmaceutical companies are showing a distinct trend never seen before: they are increasingly looking for ...

In 2024, combined Skyrizi and Rinvoq sales reached $17.7 billion, up 51% year over year, reflecting accelerating global ...

AbbVie just rewarded its shareholders again with a dividend. This stock has boosted its payout annually for more than 50 ...

AbbVie's combination antibiotic Emblaveo has gotten federal approval to treat complicated intra-abdominal infections, making it the first and only such therapy approved to fight antimicrobial ...

Polaris Capital Management stated the following regarding AbbVie Inc. (NYSE:ABBV) in its Q3 2024 investor letter: “U.S. biopharma/biotech companies topped the health care sector, with the ...

AbbVie’s Skyrizi was responsible for the highest TV advertising outlay in pharma in most months of 2024, but 2025 is starting off on a very different note. According to iSpot.TV’s analysis of ...

MongoDB is a trade and not an investment, Cramer says. Jim Cramer recommends buying AbbVie , saying it’s "just a gem." Get two weeks of free access to pro-level trading tools, including news ...